FI110993B - Menetelmä B-ryhmän streptokokkityyppien II ja V polysakkaridi-proteiinikonjugaatin valmistamiseksi - Google Patents
Menetelmä B-ryhmän streptokokkityyppien II ja V polysakkaridi-proteiinikonjugaatin valmistamiseksi Download PDFInfo
- Publication number
- FI110993B FI110993B FI951412A FI951412A FI110993B FI 110993 B FI110993 B FI 110993B FI 951412 A FI951412 A FI 951412A FI 951412 A FI951412 A FI 951412A FI 110993 B FI110993 B FI 110993B
- Authority
- FI
- Finland
- Prior art keywords
- type
- polysaccharide
- vaccine
- gbs
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 36
- 230000008569 process Effects 0.000 title claims description 6
- 150000004676 glycans Chemical class 0.000 claims abstract description 166
- 239000005017 polysaccharide Substances 0.000 claims abstract description 161
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 160
- 125000005629 sialic acid group Chemical group 0.000 claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 230000000890 antigenic effect Effects 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 238000006268 reductive amination reaction Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 150000004804 polysaccharides Polymers 0.000 claims description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 229960000814 tetanus toxoid Drugs 0.000 abstract description 37
- 239000000463 material Substances 0.000 abstract description 7
- 241000194017 Streptococcus Species 0.000 abstract description 2
- 229960003983 diphtheria toxoid Drugs 0.000 abstract description 2
- 206010043376 Tetanus Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 117
- 241000283973 Oryctolagus cuniculus Species 0.000 description 63
- 210000002966 serum Anatomy 0.000 description 37
- 229940027941 immunoglobulin g Drugs 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 230000003053 immunization Effects 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 108010060123 Conjugate Vaccines Proteins 0.000 description 10
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 10
- 229940031670 conjugate vaccine Drugs 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000002860 competitive effect Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 229960003082 galactose Drugs 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 229930182830 galactose Natural products 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000000625 opsonophagocytic effect Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000004043 trisaccharides Chemical group 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- LZIYJWQXUZGDKJ-HKVUECMASA-N (4s,5r,6r,7r)-5-acetamido-4,6,7,8-tetrahydroxy-2-oxooctanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](NC(=O)C)[C@@H](O)CC(=O)C(O)=O LZIYJWQXUZGDKJ-HKVUECMASA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- PRLDILURXJMICQ-UHFFFAOYSA-N 4-[(4-aminophenyl)methoxymethyl]aniline Chemical compound C1=CC(N)=CC=C1COCC1=CC=C(N)C=C1 PRLDILURXJMICQ-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 208000006816 Neonatal Sepsis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997092A | 1992-09-24 | 1992-09-24 | |
| US94997092 | 1992-09-24 | ||
| US12555693A | 1993-09-23 | 1993-09-23 | |
| US12555693 | 1993-09-23 | ||
| PCT/US1993/009056 WO1994006467A1 (en) | 1992-09-24 | 1993-09-24 | Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines |
| US9309056 | 1993-09-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI951412A0 FI951412A0 (fi) | 1995-03-24 |
| FI951412L FI951412L (fi) | 1995-05-24 |
| FI110993B true FI110993B (fi) | 2003-05-15 |
Family
ID=26823688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI951412A FI110993B (fi) | 1992-09-24 | 1995-03-24 | Menetelmä B-ryhmän streptokokkityyppien II ja V polysakkaridi-proteiinikonjugaatin valmistamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5795580A (de) |
| EP (1) | EP0667787B1 (de) |
| JP (3) | JP4163251B2 (de) |
| KR (1) | KR100293017B1 (de) |
| AT (1) | ATE203167T1 (de) |
| AU (1) | AU690525B2 (de) |
| CA (1) | CA2145397C (de) |
| DE (1) | DE69330464T2 (de) |
| DK (1) | DK0667787T3 (de) |
| ES (1) | ES2160601T3 (de) |
| FI (1) | FI110993B (de) |
| GR (1) | GR3036928T3 (de) |
| IL (1) | IL107103A (de) |
| NO (2) | NO319569B1 (de) |
| NZ (2) | NZ299249A (de) |
| PT (1) | PT667787E (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185666A (zh) * | 1996-11-18 | 1998-06-24 | 日本电池株式会社 | 锂电池用正极板及锂电池 |
| CA2320470A1 (en) * | 1998-02-05 | 1999-08-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
| US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| EP1320542B9 (de) | 2000-08-08 | 2007-09-12 | St. Jude Children's Research Hospital | Gruppe-b streptococcus polypeptide, nukleinsäure, therapeutische zusammensetzungen und impfstoffe davon |
| SV2003000753A (es) * | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
| US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
| US7534442B2 (en) * | 2001-08-21 | 2009-05-19 | The Brigham And Women's Hospital, Inc. | Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid |
| AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
| WO2004089407A2 (en) | 2003-03-31 | 2004-10-21 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
| US7972608B2 (en) * | 2003-06-23 | 2011-07-05 | Baxter International Inc. | Carrier proteins for vaccines |
| MX2007005202A (es) * | 2004-11-01 | 2007-07-09 | Brigham & Womens Hospital | Polisacaridos de estreptococo modificados y usos de los mismos. |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US8206726B2 (en) * | 2006-02-06 | 2012-06-26 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
| GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| EP2731617A4 (de) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | Lipidhaltige psa-zusammensetzungen, verfahren zu ihrer isolierung und verwendungsverfahren dafür |
| CA2883481A1 (en) | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic compositions |
| KR102045663B1 (ko) * | 2015-05-04 | 2019-11-15 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| WO2017031431A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
| EP3484441A4 (de) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | Glycolipidzusammensetzungen und verfahren zur verwendung |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US12521443B2 (en) | 2019-05-10 | 2026-01-13 | Glaxosmithkline Biologicals Sa | Conjugate production |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207414A (en) * | 1978-08-16 | 1980-06-10 | President And Fellows Of Harvard College | Polysaccharide antigens |
| US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
| IE51174B1 (en) * | 1980-04-14 | 1986-10-29 | Merck & Co Inc | Group b streptococcal capsular polysaccharides |
| US4438261A (en) * | 1980-05-19 | 1984-03-20 | Riker Laboratories, Inc. | Anticoagulant substance |
| US4367222A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immune globulin specific to Group B streptococci |
| US4356263A (en) * | 1980-06-09 | 1982-10-26 | President And Fellows Of Harvard College | Method of making a polysaccharide vaccine |
| US4367223A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Vaccine against Group B streptococci |
| US4367221A (en) * | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immunization against Group B streptococci |
| US4284537A (en) * | 1980-07-03 | 1981-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate of streptococcal M protein peptide vaccine |
| US4425330A (en) * | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
| US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4757134A (en) * | 1982-12-02 | 1988-07-12 | The Rockefeller University | IgA binding protein |
| EP0175261B1 (de) * | 1984-09-12 | 1991-12-11 | Chiron Corporation | Hybridpartikel-Immunogene |
| FR2581877B1 (fr) * | 1985-05-14 | 1987-12-18 | Louvain Universite Catholique | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries |
| DE3750139T2 (de) * | 1986-04-16 | 1994-10-06 | Brigham & Womens Hospital | Bakterielle antigene, antikörper, impfstoffe und deren herstellung. |
| US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
| NZ225372A (en) * | 1987-07-17 | 1991-04-26 | Xoma Corp | Immunotoxin composition comprising purified ricin-a-chain species |
| IL95578A (en) * | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus |
| WO1991008772A1 (en) * | 1989-12-14 | 1991-06-27 | National Research Council Of Canada | Improved meningococcal polysaccharide conjugate vaccine |
| FR2682388B1 (fr) * | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
-
1993
- 1993-09-24 AT AT93922357T patent/ATE203167T1/de not_active IP Right Cessation
- 1993-09-24 PT PT93922357T patent/PT667787E/pt unknown
- 1993-09-24 CA CA002145397A patent/CA2145397C/en not_active Expired - Fee Related
- 1993-09-24 AU AU51378/93A patent/AU690525B2/en not_active Ceased
- 1993-09-24 DE DE69330464T patent/DE69330464T2/de not_active Expired - Fee Related
- 1993-09-24 EP EP93922357A patent/EP0667787B1/de not_active Expired - Lifetime
- 1993-09-24 DK DK93922357T patent/DK0667787T3/da active
- 1993-09-24 NZ NZ299249A patent/NZ299249A/xx not_active IP Right Cessation
- 1993-09-24 ES ES93922357T patent/ES2160601T3/es not_active Expired - Lifetime
- 1993-09-24 KR KR1019950701137A patent/KR100293017B1/ko not_active Expired - Fee Related
- 1993-09-24 JP JP50844194A patent/JP4163251B2/ja not_active Expired - Fee Related
- 1993-09-24 NZ NZ248766A patent/NZ248766A/en not_active IP Right Cessation
- 1993-09-24 IL IL10710393A patent/IL107103A/en not_active IP Right Cessation
-
1995
- 1995-03-23 NO NO19951109A patent/NO319569B1/no not_active IP Right Cessation
- 1995-03-24 FI FI951412A patent/FI110993B/fi active
- 1995-03-24 NO NO951152A patent/NO951152D0/no unknown
- 1995-06-07 US US08/483,647 patent/US5795580A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 US US09/023,526 patent/US5993825A/en not_active Expired - Fee Related
-
2001
- 2001-10-18 GR GR20010401795T patent/GR3036928T3/el not_active IP Right Cessation
-
2005
- 2005-07-05 JP JP2005196902A patent/JP4308174B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-09 JP JP2009055767A patent/JP2009132727A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08501563A (ja) | 1996-02-20 |
| DE69330464D1 (en) | 2001-08-23 |
| AU5137893A (en) | 1994-04-12 |
| EP0667787B1 (de) | 2001-07-18 |
| CA2145397C (en) | 2007-10-30 |
| NO319569B1 (no) | 2005-08-29 |
| ES2160601T3 (es) | 2001-11-16 |
| DE69330464T2 (de) | 2001-11-08 |
| IL107103A0 (en) | 1994-08-26 |
| CA2145397A1 (en) | 1994-03-31 |
| NO951152D0 (no) | 1995-03-24 |
| EP0667787A1 (de) | 1995-08-23 |
| JP4163251B2 (ja) | 2008-10-08 |
| GR3036928T3 (en) | 2002-01-31 |
| US5795580A (en) | 1998-08-18 |
| JP2009132727A (ja) | 2009-06-18 |
| US5993825A (en) | 1999-11-30 |
| NO951109L (no) | 1995-05-22 |
| KR950703361A (ko) | 1995-09-20 |
| FI951412A0 (fi) | 1995-03-24 |
| KR100293017B1 (ko) | 2001-09-17 |
| AU690525B2 (en) | 1998-04-30 |
| DK0667787T3 (da) | 2001-10-29 |
| PT667787E (pt) | 2001-10-31 |
| NZ248766A (en) | 1996-11-26 |
| NZ299249A (en) | 2000-08-25 |
| FI951412L (fi) | 1995-05-24 |
| JP2005306884A (ja) | 2005-11-04 |
| IL107103A (en) | 2001-03-19 |
| JP4308174B2 (ja) | 2009-08-05 |
| NO951109D0 (no) | 1995-03-23 |
| ATE203167T1 (de) | 2001-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110993B (fi) | Menetelmä B-ryhmän streptokokkityyppien II ja V polysakkaridi-proteiinikonjugaatin valmistamiseksi | |
| Paoletti et al. | Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine | |
| Paoletti et al. | Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine | |
| Wessels et al. | Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine | |
| EP0754055B1 (de) | Gruppe a streptokokkenpolysaccharide immunogen-zusammensetzungen und verfahren | |
| JP2736248B2 (ja) | 莢膜ポリマーフラグメントの製造方法 | |
| US4673574A (en) | Immunogenic conjugates | |
| US4761283A (en) | Immunogenic conjugates | |
| US7449189B2 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
| US5843461A (en) | Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines | |
| CA2101648C (en) | Polysaccharide-protein conjugates | |
| US4762713A (en) | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers |